Plus Therapeutics, Inc.
PSTV
$0.7691
-$0.075-8.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.54% | 15.03% | 22.92% | 43.85% | 34.32% |
| Total Depreciation and Amortization | 15.13% | -8.54% | -14.19% | -10.46% | -11.80% |
| Total Amortization of Deferred Charges | -89.47% | -79.17% | -68.62% | -58.82% | -51.16% |
| Total Other Non-Cash Items | -301.97% | -336.06% | -172.83% | 28.98% | 26.12% |
| Change in Net Operating Assets | 388.71% | 621.73% | 427.55% | -130.05% | -119.94% |
| Cash from Operations | 17.87% | 15.00% | 33.83% | 22.28% | 0.93% |
| Capital Expenditure | 8.75% | 28.05% | 35.69% | 73.99% | 68.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -3,552.99% | -3,557.26% | -376.92% | -- |
| Cash from Investing | -2,469.38% | -3,168.99% | -2,675.00% | -53.05% | 78.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -148.51% | -173.51% | -198.51% | 0.00% | 0.00% |
| Issuance of Common Stock | 31.45% | 24.49% | 1.63% | -48.72% | -65.09% |
| Repurchase of Common Stock | -196.83% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 45.79% | 54.98% | 54.98% | 54.98% |
| Cash from Financing | 79.59% | 38.91% | 2.43% | -67.29% | -74.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.37% | -5.65% | 16.85% | -15.34% | -3,316.43% |